Aaron Bartek
Nurse Practitioner · Wahoo, NENPI 1194292813
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,710 of the $10,905 with a category attached, or 79.9%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,826, 2.9 times the $1,317 reported in 2021. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 521 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$2K
- Biogen$2K
- Novartis$1K
- AbbVie$894
- EMD Serono, Inc.$816
- Bristol Myers Squibb$758
- plus $3K from 28 others
Across 2 payments — averaging $5177.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$10K
What the payments were for
- Consulting fees$1,93518%
- Speaking & faculty fees$410%
- Food & beverage$8,71080%
- Education$2192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 27 | $2,313 |
| Biogen | 103 | $1,718 |
| Novartis | 107 | $1,373 |
| AbbVie(2 entities) | 54 | $894 |
| EMD Serono, Inc. | 41 | $816 |
| Bristol Myers Squibb | 46 | $758 |
| Sanofi | 24 | $607 |
| Lilly USA, LLC | 20 | $340 |
| Genentech USA, Inc. | 14 | $287 |
| Johnson & Johnson | 7 | $201 |
| Mallinckrodt Hospital Products Inc. | 9 | $182 |
| ANI Pharmaceuticals, Inc. | 9 | $169 |
| Vanda Pharmaceuticals Inc. | 6 | $165 |
| Ipsen Biopharmaceuticals, Inc | 7 | $136 |
| Otsuka America Pharmaceutical, Inc. | 7 | $127 |
| Piramal Critical Care | 1 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $89 |
| Banner Life Sciences, LLC | 4 | $89 |
| Lundbeck LLC | 4 | $72 |
| Acorda Therapeutics, Inc | 3 | $61 |
| Pfizer | 3 | $54 |
| Medtronic | 2 | $50 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| Cycle Pharmaceuticals Inc | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Merz Pharmaceuticals, LLC | 1 | $17 |
| 180 Medical, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Sandoz | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,905 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 49 | $453,490 |
| VumerityDiroximel Fumarate | 29 | $263,766 |
| Teriflunomide | 67 | $171,045 |
| AubagioTeriflunomide | 19 | $145,847 |
| BafiertamMonomethyl Fumarate | 19 | $136,227 |
| ZeposiaOzanimod Hydrochloride | 14 | $124,297 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $112,837 |
| HorizantGabapentin Enacarbil | 12 | $12,784 |
| MyrbetriqMirabegron | 24 | $10,799 |
| Dalfampridine ErDalfampridine | 29 | $4,486 |
| Cyclosporine | 22 | $4,446 |
| Dimethyl Fumarate | 23 | $3,699 |
| Baclofen | 101 | $2,028 |
| Modafinil | 28 | $1,207 |
| Oxcarbazepine | 11 | $1,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $1,718 | $263,76629 claims |
| SanofiAubagio | $607 | $145,84719 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $40 | $12,78412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Wahoo
- Melissa FultonWahoo$10K
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Winifred SchaedelPalmyra$64K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Jodi FuehrerGrand Island$25K
- Amanda GuggenmosOmaha$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.